Search results for "Molecular Response"

showing 10 items of 13 documents

Characterization of cellular and molecular responses of Actinia equina (Linnaeus, 1758)

2014

Actinia equinamolecular responsecellular responses
researchProduct

Profiling the physiological and molecular response to sulfonamidic drag in Procambarus clarkii

2014

Sulfamethoxazole (SMZ) is one of the most widely employed sulfonamides. Because of the widespread use of SMZ, a considerable amount is indeed expected to be introduced into the environment. The cytotoxicity of SMZ relies mainly on arylhydroxylamine metabolites (S-NOH) of SMZ and it is associated with the production of reactive oxygen species (ROS). There is limited information about the toxic potential of SMZ at the cellular and molecular levels, especially in aquatic and/or non-target organisms. In the present study, the red swamp crayfish (Procambarus clarkii), being tolerant to extreme environmental conditions and resistant to disease, was used as a model organism to profile the molecula…

Blood GlucoseGillsHemocytesAntioxidantSulfamethoxazolePhysiologyHealth Toxicology and Mutagenesismedicine.medical_treatmentHepatopancreasHaemolymphatic parametersAquacultureAstacoideaToxicologyBiochemistryArthropod ProteinsAnti-Infective AgentsRed swamp crayfishStress PhysiologicalGene expressionmedicineAnimalsMetallothioneinHSP70 Heat-Shock ProteinsTissue DistributionAntiossidanti enzymesharmony patio parameters proinflammatory genes red swap crac fish sulfametoxazoleProcambarus clarkiichemistry.chemical_classificationReactive oxygen speciesbiologyGene Expression Regulation DevelopmentalProinflammatory genesCell BiologyGeneral Medicinebiology.organism_classificationBlood Cell CountHsp70FerritinBiochemistrychemistryMolecular ResponseFerritinsbiology.proteinMetallothioneinAntioxidant enzymesOxidoreductasesBiomarkersWater Pollutants Chemical
researchProduct

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib

2019

A reduction in BCR-ABL1/ABL1IS transcript levels to &lt

Male0301 basic medicineOncologyTreatment outcomeFusion Proteins bcr-ablAntineoplastic Agentlcsh:ChemistryBcr abl10302 clinical medicinehemic and lymphatic diseasesimatinib mesylateBCR-ABL1; European Leukemia Net; chronic myeloid leukemia; early molecular response; imatinib mesylatelcsh:QH301-705.5<i>BCR-ABL1</i>SpectroscopyAged 80 and overGeneral MedicineMiddle AgedComputer Science ApplicationsTreatment Outcome030220 oncology & carcinogenesisFemaleHumanmedicine.drugAdultmedicine.medical_specialtyProtein Kinase InhibitorAntineoplastic AgentsArticleCatalysisEuropean Leukemia NetInorganic Chemistry03 medical and health scienceschronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineBiomarkers TumormedicineHumansIn patientRNA MessengerPhysical and Theoretical ChemistryProtein Kinase InhibitorsMolecular BiologyAgedbusiness.industryOrganic ChemistryImatinibBCR-ABL1030104 developmental biologyImatinib mesylatelcsh:Biology (General)lcsh:QD1-999early molecular responsebusiness
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

2019

Discontinuation of tyrosine kinase inhibitors (TKIs) therapy is now feasible for patients with chronic myeloid leukemia (CML) with deep and longstanding molecular response (MR 4/4.5); around 40–60%...

OncologyDrugAdultMaleCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAntineoplastic AgentsDisease-Free Survival03 medical and health sciencesMyelogenous0302 clinical medicinehemic and lymphatic diseasesInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansProtein Kinase Inhibitorsmedia_commonWithholding TreatmentDose-Response Relationship Drugbusiness.industryMyeloid leukemiaHematologyProtein-Tyrosine Kinasesmedicine.diseaseDiscontinuationLeukemiaPyrimidinesOncologyWithholding Treatment030220 oncology & carcinogenesisMolecular ResponseImatinib MesylateFemalebusinessTyrosine kinase030215 immunologyFollow-Up StudiesLeukemialymphoma
researchProduct

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at T…

2021

Molecular testing of the BCR-ABL1 transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the molecular procedure has been standardized and optimized, including the total white blood cells (WBCs) and RNA isolation methods. Here, we compare the performance of our current manual protocol to a newly semiautomatic method based on the Biomek i-5 Automated Workstations integrated with the CytoFLEX Flow Cytometer, followed by the automatic QIAsymphony system to facilitate high-throughput processing samples and reduce the hands-on time a…

OncologyMedicine (General)medicine.medical_specialtyBCR-ABL1/ABL1Q-PCRbusiness.industrychronic myeloid leukaemiaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)SARS-CoV-2 infectionClinical BiochemistrySample processingmolecular responseBCR-ABL1/ABL1ISChronic myeloid leukaemiaArticle<i>BCR-ABL1/ABL1<sup>IS</sup></i>R5-920Real-time polymerase chain reactionInternal medicinehemic and lymphatic diseasesMolecular ProcedureISmedicineRNA extractionbusinessDiagnostics
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Molecular response of Saccharomyces cerevisiae wine and laboratory strains to high sugar stress conditions.

2010

One of the stress conditions that can affect Saccharomyces cerevisiae cells during their growth is osmotic stress. Under particular environments (for instance, during the production of alcoholic beverages) yeasts have to cope with osmotic stress caused by high sugar concentrations. Although the molecular changes and pathways involved in the response to saline or sorbitol stress are widely understood, less is known about how cells respond to high sugar concentrations. In this work we present a comprehensive study of the response to this form of stress which indicates important transcriptomic changes, especially in terms of the genes involved in both stress response and respiration, and the i…

Saccharomyces cerevisiae ProteinsOsmotic shockProteomeMutantSaccharomyces cerevisiaeWineSaccharomyces cerevisiaeBiologyMicrobiologychemistry.chemical_compoundStress PhysiologicalGene Expression Regulation FungalGene expressionPhosphorylationOligonucleotide Array Sequence AnalysisGene Expression ProfilingRNA FungalGeneral Medicinebiology.organism_classificationYeastGlucosechemistryBiochemistryMolecular ResponseProteomeMutationSorbitolMitogen-Activated Protein KinasesFood ScienceInternational journal of food microbiology
researchProduct

Combined effect of cadmium and sulfonamides on sea urchin development

2013

Echinoderms play a key role in the maintenance of the integrity of the ecosystem where they live. They are constantly exposed to pollutants, particularly in their early planktonic life stages. Sulfamethoxazole with trimethoprim (TMP/SMX) is a fixed antibiotic combination whose concentration is significantly increasing in the coastal waters due to human medicine and also intensive husbandry and aquaculture activities. Previously, we studied the defense strategies activated by P. lividus embryos in response to sublethal doses of CdCl2. Although toxic effects of cadmium on embryo development are not morphologically detectable before 24 hours of exposure, we found upregulation in mRNAs related …

Settore BIO/11 - Biologia Molecolaresea urchin metallothionein stress molecular response gene expression
researchProduct

Gene Expression Profile of Chronic Myeloid Leukemia Innately Resistant to Imatinib

2007

Background. Most chronic myeloid leukemia patients who receive imatinib as first line-terapy will obtain, after 12 months treatment, complete cytogenetic and molecular response . However several cases will not achieve molecular response, but their innate mechanism(s) of resistance remain poorly understood. We tried to explore the molecular events involved in innate resistance in CML. Study design. Five patients who were molecular “non responder” and seven “major” responder were investigated by using the expression profile of a set of 380 genes. Multiple testing procedure (MTP), Significance Analysis of Microarrays (SAM), Empirical Bayes Analysis of Microarrays (EBAM), False Discovery Rate (…

business.industryMyeloid leukemiaImatinibGeneral MedicineCell cycleMolecular ResponseImmunologySignificance analysis of microarraysCancer researchmedicineEpigeneticsDNA microarraybusinessGenemedicine.drugClinical Leukemia
researchProduct